English

    Overview

  • Dr. G Rama Mohan Reddy is a distinguished nuclear medicine specialist in Yelahanka. He is currently practising as a Lead consultant - Nuclear Medicine at Manipal Hospitals, Yelahanka, bringing over 15 years of focused experience in PET-CT imaging, advanced molecular diagnostics, and therapeutic nuclear medicine. With an academic foundation as an MBBS graduate of Kurnool Medical College and an MD in Nuclear Medicine from the All India Institute of Medical Sciences (AIIMS), New Delhi, he has developed deep expertise in advanced nuclear imaging and radionuclide-based therapies. His structured MD training, followed by senior residency, laid the foundation for high-volume exposure to comprehensive nuclear medicine services, including diagnostic imaging, hybrid imaging technologies, and radionuclide therapy.

  • Dr. Reddy has extensive expertise in PET-CT imaging, having interpreted and supervised more than 50,000 18F-FDG PET-CT scans across oncology, cardiac, and neurological indications. His experience includes 68Ga DOTANOC imaging for neuroendocrine tumours (over 5000 cases), 68Ga PSMA imaging for prostate cancer, 18F-DOPA studies in brain tumours and movement disorders, 18F-NaF bone imaging, and 13N-ammonia myocardial perfusion imaging. This depth of hybrid imaging experience places him among the best nuclear medicine specialists in Yelahanka for oncological and molecular imaging services.

  • Beyond PET-CT, his general nuclear medicine work spans genitourinary scans, hepatobiliary imaging, endocrine evaluations, CNS imaging, skeletal studies, lymphoscintigraphy, RBC labelling, gastrointestinal applications, and lung perfusion studies. In nuclear cardiology, he has performed myocardial perfusion imaging using Tc-99m and Thallium tracers, viability assessments using FDG combinations, and radionuclide ventriculography.

  • Therapeutic nuclear medicine forms a significant component of his practice. He has extensive experience in radioiodine therapy for thyroid cancer and hyperthyroidism, with involvement in high patient volumes in dedicated thyroid clinics. His work also includes diagnosis and treatment of neuroendocrine tumours using 68Ga DOTANOC imaging and 177Lutetium therapy; prostate cancer management with 68Ga PSMA imaging and 177Lutetium therapy; 131I MIBG therapy for neuroblastoma and pheochromocytoma; 188Rhenium radiosynovectomy for chronic arthritic conditions; and bone pain palliation using 153Samarium and 89Strontium.

  • Dr. Reddy has several years of experience working with GE and Siemens nuclear imaging systems and is a qualified Radiological Safety Officer. His academic profile includes 13 indexed international publications, 10 international abstracts, and a book chapter contribution in nuclear medicine imaging. His research work spans oncologic PET-CT applications, hybrid SPECT-CT evaluation, thyroid disease management, and molecular imaging advancements.

  • At Manipal Hospital, Yelahanka, Dr. Reddy delivers comprehensive nuclear medicine services integrating advanced imaging, molecular diagnostics, and radionuclide therapy within a multidisciplinary oncology framework. His experience across high-volume PET-CT reporting, therapeutic isotope applications, and academic contributions positions him among the best nuclear medicine specialists in Yelahanka for advanced PET-CT and targeted radionuclide care.

    • Field of Expertise

  • PET-CT Imaging (FDG, PSMA, DOTANOC, DOPA, NaF)
  • Thyroid Cancer & Hyperthyroidism Management (131I Therapy)
  • Theranostics (177Lu Therapy for NET & Prostate Cancer)
  • Nuclear Cardiology & Myocardial Perfusion Imaging
  • Radiosynovectomy for Chronic Arthritis
  • Bone Pain Palliation Using 153Samarium & 89Strontium

    • Languages Spoken

  • English
  • Kannada
  • Telugu
  • Hindi

    • Talks & Publications

  • Sharma P, Singh H, Suman SK, Sharma A, Reddy RM, Thulkar S, Bal C, Malhotra A, Kumar R.18F-FDG PET-CT for detecting recurrent gastric adenocarcinoma: results from a Non-Oriental Asian population. Nucl Med Commun. 2012 Sep;33(9):960-6.
  • Shamim SA, Kumar R, Halanaik D, Shandal V, Reddy RM, Bal CS, Malhotra A. Detection of recurrent disease in colorectal cancer. Nucl Med Commun 2010 Jun; 31(6);590-6.
  • Santra A, Kumar R, Reddy R, Halanaik D, Kumar R, Bal CS, Malhotra A.FDG PET –CT in the management of primary breast lymphoma, Clin Nucl Med. 2009 Dec;34(12):848-53.
  • Sharma P, Kumar R, Singh H, Jeph S, Patnecha M, Reddy RM, Naswa N, Bal C, Malhotra A. Imaging thrombus in cancer patients with FDG PET-CT. Jpn J Radiol. 2012 Feb;30(2):95-104. Epub 2011 Dec 22.
  • Sharma P, Dhull VS, Reddy RM, Bal C, Thulkar S, Malhotra A, Kumar R. Hybrid SPECT-CT for characterizing isolated vertebral lesions observed by bone scintigraphy: comparison with planar scintigraphy, SPECT, and CT. Diagn Interv Radiol. 2012 Aug 3. doi: 10.4261/1305-3825.DIR.5790-12.1. [Epub ahead of print]
  • Sharma JB, Karmakar D, Kumar R, Shamim SA, Kumar S, Singh N, Roy KK, Reddy RM Comparison of PET/CT with other imaging modalities in women with genital tuberculosis. Int J Gynaecol Obstet. 2012 Aug;118(2):123-8. Epub 2012 May 30
  • Sharma P, Dhull VS, Jeph S, Reddy RM, Singh H, Naswa N, Bal C, Kumar R. Can hybrid SPECT-CT overcome the limitations associated with poor imaging properties of 131I-MIBG? Comparison with planar scintigraphy and SPECT in pheochromocytoma. Clin Nucl Med. (In Press).
  • Naswa N, Sharma P, Gupta SK, Karunanithi S, Reddy RM, Patnecha M, Lata S, Kumar R, Malhotra A, Bal C. Dual tracer functional imaging of Gastroenteropancreatic Neuroendocrine tumors using 18F-FDG PET-CT and 68Ga-DOTANOC PET-CT: Competitive or Complimentary? Clin Nucl Med. (In Press).
  • Damle N, Bal C, Reddy R, Kumar P, Vireka D. Short term outcome of empirical low fixed dose radioiodine therapy in diffuse toxic goiter. Hormones- International Journal of Endocrinology and Metabolism. (In Press)
  • Chawla M, Reddy R, Kumar R, Das CJ, Agarwala S, Tiwari AM, Malhotra A, Kumar R. Role of FDG PET?CT in detection of meningeal metastasis in neuroblastoma. Pediatr Surg Int.2009 Feb;25(2):211-5
  • Singh H, Sharma P, Suman K C S, Reddy RM, Bal C, Malhotra A, Kumar R. Postorchiectomy intrascrotal hematoma mimicking local recurrence on 18F-FDG PET/CT: a diagnostic dilemma. Clin Nucl Med. 2012 May;37(5):e102-3.
  • Singh H, Sharma P, Reddy RM, Bal C, Malhotra A, Kumar R. Sister Mary Joseph's Nodule in endometrial carcinoma: Detection with FDG PET-CT. Clin Nucl Med (In Press)
  • Singla S, Gupta S, Reddy RM, Durgapal P, Bal CS.68Ga-DOTA-NOC PET and Peptide Receptor Radionuclide Therapy in Management of Bilateral Ovarian Metastases from Gastrointestinal Carcinoid.Jpn J Clin Oncol. 2012 Oct 28. [Epub ahead of print]

    Languages Spoken

  • English
  • Kannada
  • Telugu
  • Hindi

    • Overview

  • Dr. G Rama Mohan Reddy is a distinguished nuclear medicine specialist in Yelahanka. He is currently practising as a Lead consultant - Nuclear Medicine at Manipal Hospitals, Yelahanka, bringing over 15 years of focused experience in PET-CT imaging, advanced molecular diagnostics, and therapeutic nuclear medicine. With an academic foundation as an MBBS graduate of Kurnool Medical College and an MD in Nuclear Medicine from the All India Institute of Medical Sciences (AIIMS), New Delhi, he has developed deep expertise in advanced nuclear imaging and radionuclide-based therapies. His structured MD training, followed by senior residency, laid the foundation for high-volume exposure to comprehensive nuclear medicine services, including diagnostic imaging, hybrid imaging technologies, and radionuclide therapy.

  • Dr. Reddy has extensive expertise in PET-CT imaging, having interpreted and supervised more than 50,000 18F-FDG PET-CT scans across oncology, cardiac, and neurological indications. His experience includes 68Ga DOTANOC imaging for neuroendocrine tumours (over 5000 cases), 68Ga PSMA imaging for prostate cancer, 18F-DOPA studies in brain tumours and movement disorders, 18F-NaF bone imaging, and 13N-ammonia myocardial perfusion imaging. This depth of hybrid imaging experience places him among the best nuclear medicine specialists in Yelahanka for oncological and molecular imaging services.

  • Beyond PET-CT, his general nuclear medicine work spans genitourinary scans, hepatobiliary imaging, endocrine evaluations, CNS imaging, skeletal studies, lymphoscintigraphy, RBC labelling, gastrointestinal applications, and lung perfusion studies. In nuclear cardiology, he has performed myocardial perfusion imaging using Tc-99m and Thallium tracers, viability assessments using FDG combinations, and radionuclide ventriculography.

  • Therapeutic nuclear medicine forms a significant component of his practice. He has extensive experience in radioiodine therapy for thyroid cancer and hyperthyroidism, with involvement in high patient volumes in dedicated thyroid clinics. His work also includes diagnosis and treatment of neuroendocrine tumours using 68Ga DOTANOC imaging and 177Lutetium therapy; prostate cancer management with 68Ga PSMA imaging and 177Lutetium therapy; 131I MIBG therapy for neuroblastoma and pheochromocytoma; 188Rhenium radiosynovectomy for chronic arthritic conditions; and bone pain palliation using 153Samarium and 89Strontium.

  • Dr. Reddy has several years of experience working with GE and Siemens nuclear imaging systems and is a qualified Radiological Safety Officer. His academic profile includes 13 indexed international publications, 10 international abstracts, and a book chapter contribution in nuclear medicine imaging. His research work spans oncologic PET-CT applications, hybrid SPECT-CT evaluation, thyroid disease management, and molecular imaging advancements.

  • At Manipal Hospital, Yelahanka, Dr. Reddy delivers comprehensive nuclear medicine services integrating advanced imaging, molecular diagnostics, and radionuclide therapy within a multidisciplinary oncology framework. His experience across high-volume PET-CT reporting, therapeutic isotope applications, and academic contributions positions him among the best nuclear medicine specialists in Yelahanka for advanced PET-CT and targeted radionuclide care.

    • Field of Expertise

  • PET-CT Imaging (FDG, PSMA, DOTANOC, DOPA, NaF)
  • Thyroid Cancer & Hyperthyroidism Management (131I Therapy)
  • Theranostics (177Lu Therapy for NET & Prostate Cancer)
  • Nuclear Cardiology & Myocardial Perfusion Imaging
  • Radiosynovectomy for Chronic Arthritis
  • Bone Pain Palliation Using 153Samarium & 89Strontium

    • Talks & Publications

  • Sharma P, Singh H, Suman SK, Sharma A, Reddy RM, Thulkar S, Bal C, Malhotra A, Kumar R.18F-FDG PET-CT for detecting recurrent gastric adenocarcinoma: results from a Non-Oriental Asian population. Nucl Med Commun. 2012 Sep;33(9):960-6.
  • Shamim SA, Kumar R, Halanaik D, Shandal V, Reddy RM, Bal CS, Malhotra A. Detection of recurrent disease in colorectal cancer. Nucl Med Commun 2010 Jun; 31(6);590-6.
  • Santra A, Kumar R, Reddy R, Halanaik D, Kumar R, Bal CS, Malhotra A.FDG PET –CT in the management of primary breast lymphoma, Clin Nucl Med. 2009 Dec;34(12):848-53.
  • Sharma P, Kumar R, Singh H, Jeph S, Patnecha M, Reddy RM, Naswa N, Bal C, Malhotra A. Imaging thrombus in cancer patients with FDG PET-CT. Jpn J Radiol. 2012 Feb;30(2):95-104. Epub 2011 Dec 22.
  • Sharma P, Dhull VS, Reddy RM, Bal C, Thulkar S, Malhotra A, Kumar R. Hybrid SPECT-CT for characterizing isolated vertebral lesions observed by bone scintigraphy: comparison with planar scintigraphy, SPECT, and CT. Diagn Interv Radiol. 2012 Aug 3. doi: 10.4261/1305-3825.DIR.5790-12.1. [Epub ahead of print]
  • Sharma JB, Karmakar D, Kumar R, Shamim SA, Kumar S, Singh N, Roy KK, Reddy RM Comparison of PET/CT with other imaging modalities in women with genital tuberculosis. Int J Gynaecol Obstet. 2012 Aug;118(2):123-8. Epub 2012 May 30
  • Sharma P, Dhull VS, Jeph S, Reddy RM, Singh H, Naswa N, Bal C, Kumar R. Can hybrid SPECT-CT overcome the limitations associated with poor imaging properties of 131I-MIBG? Comparison with planar scintigraphy and SPECT in pheochromocytoma. Clin Nucl Med. (In Press).
  • Naswa N, Sharma P, Gupta SK, Karunanithi S, Reddy RM, Patnecha M, Lata S, Kumar R, Malhotra A, Bal C. Dual tracer functional imaging of Gastroenteropancreatic Neuroendocrine tumors using 18F-FDG PET-CT and 68Ga-DOTANOC PET-CT: Competitive or Complimentary? Clin Nucl Med. (In Press).
  • Damle N, Bal C, Reddy R, Kumar P, Vireka D. Short term outcome of empirical low fixed dose radioiodine therapy in diffuse toxic goiter. Hormones- International Journal of Endocrinology and Metabolism. (In Press)
  • Chawla M, Reddy R, Kumar R, Das CJ, Agarwala S, Tiwari AM, Malhotra A, Kumar R. Role of FDG PET?CT in detection of meningeal metastasis in neuroblastoma. Pediatr Surg Int.2009 Feb;25(2):211-5
  • Singh H, Sharma P, Suman K C S, Reddy RM, Bal C, Malhotra A, Kumar R. Postorchiectomy intrascrotal hematoma mimicking local recurrence on 18F-FDG PET/CT: a diagnostic dilemma. Clin Nucl Med. 2012 May;37(5):e102-3.
  • Singh H, Sharma P, Reddy RM, Bal C, Malhotra A, Kumar R. Sister Mary Joseph's Nodule in endometrial carcinoma: Detection with FDG PET-CT. Clin Nucl Med (In Press)
  • Singla S, Gupta S, Reddy RM, Durgapal P, Bal CS.68Ga-DOTA-NOC PET and Peptide Receptor Radionuclide Therapy in Management of Bilateral Ovarian Metastases from Gastrointestinal Carcinoid.Jpn J Clin Oncol. 2012 Oct 28. [Epub ahead of print]

    Field of Expertise

  • PET-CT Imaging (FDG, PSMA, DOTANOC, DOPA, NaF)
  • Thyroid Cancer & Hyperthyroidism Management (131I Therapy)
  • Theranostics (177Lu Therapy for NET & Prostate Cancer)
  • Nuclear Cardiology & Myocardial Perfusion Imaging
  • Radiosynovectomy for Chronic Arthritis
  • Bone Pain Palliation Using 153Samarium & 89Strontium

    • Languages Spoken

  • English
  • Kannada
  • Telugu
  • Hindi

    • Talks & Publications

  • Sharma P, Singh H, Suman SK, Sharma A, Reddy RM, Thulkar S, Bal C, Malhotra A, Kumar R.18F-FDG PET-CT for detecting recurrent gastric adenocarcinoma: results from a Non-Oriental Asian population. Nucl Med Commun. 2012 Sep;33(9):960-6.
  • Shamim SA, Kumar R, Halanaik D, Shandal V, Reddy RM, Bal CS, Malhotra A. Detection of recurrent disease in colorectal cancer. Nucl Med Commun 2010 Jun; 31(6);590-6.
  • Santra A, Kumar R, Reddy R, Halanaik D, Kumar R, Bal CS, Malhotra A.FDG PET –CT in the management of primary breast lymphoma, Clin Nucl Med. 2009 Dec;34(12):848-53.
  • Sharma P, Kumar R, Singh H, Jeph S, Patnecha M, Reddy RM, Naswa N, Bal C, Malhotra A. Imaging thrombus in cancer patients with FDG PET-CT. Jpn J Radiol. 2012 Feb;30(2):95-104. Epub 2011 Dec 22.
  • Sharma P, Dhull VS, Reddy RM, Bal C, Thulkar S, Malhotra A, Kumar R. Hybrid SPECT-CT for characterizing isolated vertebral lesions observed by bone scintigraphy: comparison with planar scintigraphy, SPECT, and CT. Diagn Interv Radiol. 2012 Aug 3. doi: 10.4261/1305-3825.DIR.5790-12.1. [Epub ahead of print]
  • Sharma JB, Karmakar D, Kumar R, Shamim SA, Kumar S, Singh N, Roy KK, Reddy RM Comparison of PET/CT with other imaging modalities in women with genital tuberculosis. Int J Gynaecol Obstet. 2012 Aug;118(2):123-8. Epub 2012 May 30
  • Sharma P, Dhull VS, Jeph S, Reddy RM, Singh H, Naswa N, Bal C, Kumar R. Can hybrid SPECT-CT overcome the limitations associated with poor imaging properties of 131I-MIBG? Comparison with planar scintigraphy and SPECT in pheochromocytoma. Clin Nucl Med. (In Press).
  • Naswa N, Sharma P, Gupta SK, Karunanithi S, Reddy RM, Patnecha M, Lata S, Kumar R, Malhotra A, Bal C. Dual tracer functional imaging of Gastroenteropancreatic Neuroendocrine tumors using 18F-FDG PET-CT and 68Ga-DOTANOC PET-CT: Competitive or Complimentary? Clin Nucl Med. (In Press).
  • Damle N, Bal C, Reddy R, Kumar P, Vireka D. Short term outcome of empirical low fixed dose radioiodine therapy in diffuse toxic goiter. Hormones- International Journal of Endocrinology and Metabolism. (In Press)
  • Chawla M, Reddy R, Kumar R, Das CJ, Agarwala S, Tiwari AM, Malhotra A, Kumar R. Role of FDG PET?CT in detection of meningeal metastasis in neuroblastoma. Pediatr Surg Int.2009 Feb;25(2):211-5
  • Singh H, Sharma P, Suman K C S, Reddy RM, Bal C, Malhotra A, Kumar R. Postorchiectomy intrascrotal hematoma mimicking local recurrence on 18F-FDG PET/CT: a diagnostic dilemma. Clin Nucl Med. 2012 May;37(5):e102-3.
  • Singh H, Sharma P, Reddy RM, Bal C, Malhotra A, Kumar R. Sister Mary Joseph's Nodule in endometrial carcinoma: Detection with FDG PET-CT. Clin Nucl Med (In Press)
  • Singla S, Gupta S, Reddy RM, Durgapal P, Bal CS.68Ga-DOTA-NOC PET and Peptide Receptor Radionuclide Therapy in Management of Bilateral Ovarian Metastases from Gastrointestinal Carcinoid.Jpn J Clin Oncol. 2012 Oct 28. [Epub ahead of print]

    • Overview

  • Dr. G Rama Mohan Reddy is a distinguished nuclear medicine specialist in Yelahanka. He is currently practising as a Lead consultant - Nuclear Medicine at Manipal Hospitals, Yelahanka, bringing over 15 years of focused experience in PET-CT imaging, advanced molecular diagnostics, and therapeutic nuclear medicine. With an academic foundation as an MBBS graduate of Kurnool Medical College and an MD in Nuclear Medicine from the All India Institute of Medical Sciences (AIIMS), New Delhi, he has developed deep expertise in advanced nuclear imaging and radionuclide-based therapies. His structured MD training, followed by senior residency, laid the foundation for high-volume exposure to comprehensive nuclear medicine services, including diagnostic imaging, hybrid imaging technologies, and radionuclide therapy.

  • Dr. Reddy has extensive expertise in PET-CT imaging, having interpreted and supervised more than 50,000 18F-FDG PET-CT scans across oncology, cardiac, and neurological indications. His experience includes 68Ga DOTANOC imaging for neuroendocrine tumours (over 5000 cases), 68Ga PSMA imaging for prostate cancer, 18F-DOPA studies in brain tumours and movement disorders, 18F-NaF bone imaging, and 13N-ammonia myocardial perfusion imaging. This depth of hybrid imaging experience places him among the best nuclear medicine specialists in Yelahanka for oncological and molecular imaging services.

  • Beyond PET-CT, his general nuclear medicine work spans genitourinary scans, hepatobiliary imaging, endocrine evaluations, CNS imaging, skeletal studies, lymphoscintigraphy, RBC labelling, gastrointestinal applications, and lung perfusion studies. In nuclear cardiology, he has performed myocardial perfusion imaging using Tc-99m and Thallium tracers, viability assessments using FDG combinations, and radionuclide ventriculography.

  • Therapeutic nuclear medicine forms a significant component of his practice. He has extensive experience in radioiodine therapy for thyroid cancer and hyperthyroidism, with involvement in high patient volumes in dedicated thyroid clinics. His work also includes diagnosis and treatment of neuroendocrine tumours using 68Ga DOTANOC imaging and 177Lutetium therapy; prostate cancer management with 68Ga PSMA imaging and 177Lutetium therapy; 131I MIBG therapy for neuroblastoma and pheochromocytoma; 188Rhenium radiosynovectomy for chronic arthritic conditions; and bone pain palliation using 153Samarium and 89Strontium.

  • Dr. Reddy has several years of experience working with GE and Siemens nuclear imaging systems and is a qualified Radiological Safety Officer. His academic profile includes 13 indexed international publications, 10 international abstracts, and a book chapter contribution in nuclear medicine imaging. His research work spans oncologic PET-CT applications, hybrid SPECT-CT evaluation, thyroid disease management, and molecular imaging advancements.

  • At Manipal Hospital, Yelahanka, Dr. Reddy delivers comprehensive nuclear medicine services integrating advanced imaging, molecular diagnostics, and radionuclide therapy within a multidisciplinary oncology framework. His experience across high-volume PET-CT reporting, therapeutic isotope applications, and academic contributions positions him among the best nuclear medicine specialists in Yelahanka for advanced PET-CT and targeted radionuclide care.

    Talks & Publications

  • Sharma P, Singh H, Suman SK, Sharma A, Reddy RM, Thulkar S, Bal C, Malhotra A, Kumar R.18F-FDG PET-CT for detecting recurrent gastric adenocarcinoma: results from a Non-Oriental Asian population. Nucl Med Commun. 2012 Sep;33(9):960-6.
  • Shamim SA, Kumar R, Halanaik D, Shandal V, Reddy RM, Bal CS, Malhotra A. Detection of recurrent disease in colorectal cancer. Nucl Med Commun 2010 Jun; 31(6);590-6.
  • Santra A, Kumar R, Reddy R, Halanaik D, Kumar R, Bal CS, Malhotra A.FDG PET –CT in the management of primary breast lymphoma, Clin Nucl Med. 2009 Dec;34(12):848-53.
  • Sharma P, Kumar R, Singh H, Jeph S, Patnecha M, Reddy RM, Naswa N, Bal C, Malhotra A. Imaging thrombus in cancer patients with FDG PET-CT. Jpn J Radiol. 2012 Feb;30(2):95-104. Epub 2011 Dec 22.
  • Sharma P, Dhull VS, Reddy RM, Bal C, Thulkar S, Malhotra A, Kumar R. Hybrid SPECT-CT for characterizing isolated vertebral lesions observed by bone scintigraphy: comparison with planar scintigraphy, SPECT, and CT. Diagn Interv Radiol. 2012 Aug 3. doi: 10.4261/1305-3825.DIR.5790-12.1. [Epub ahead of print]
  • Sharma JB, Karmakar D, Kumar R, Shamim SA, Kumar S, Singh N, Roy KK, Reddy RM Comparison of PET/CT with other imaging modalities in women with genital tuberculosis. Int J Gynaecol Obstet. 2012 Aug;118(2):123-8. Epub 2012 May 30
  • Sharma P, Dhull VS, Jeph S, Reddy RM, Singh H, Naswa N, Bal C, Kumar R. Can hybrid SPECT-CT overcome the limitations associated with poor imaging properties of 131I-MIBG? Comparison with planar scintigraphy and SPECT in pheochromocytoma. Clin Nucl Med. (In Press).
  • Naswa N, Sharma P, Gupta SK, Karunanithi S, Reddy RM, Patnecha M, Lata S, Kumar R, Malhotra A, Bal C. Dual tracer functional imaging of Gastroenteropancreatic Neuroendocrine tumors using 18F-FDG PET-CT and 68Ga-DOTANOC PET-CT: Competitive or Complimentary? Clin Nucl Med. (In Press).
  • Damle N, Bal C, Reddy R, Kumar P, Vireka D. Short term outcome of empirical low fixed dose radioiodine therapy in diffuse toxic goiter. Hormones- International Journal of Endocrinology and Metabolism. (In Press)
  • Chawla M, Reddy R, Kumar R, Das CJ, Agarwala S, Tiwari AM, Malhotra A, Kumar R. Role of FDG PET?CT in detection of meningeal metastasis in neuroblastoma. Pediatr Surg Int.2009 Feb;25(2):211-5
  • Singh H, Sharma P, Suman K C S, Reddy RM, Bal C, Malhotra A, Kumar R. Postorchiectomy intrascrotal hematoma mimicking local recurrence on 18F-FDG PET/CT: a diagnostic dilemma. Clin Nucl Med. 2012 May;37(5):e102-3.
  • Singh H, Sharma P, Reddy RM, Bal C, Malhotra A, Kumar R. Sister Mary Joseph's Nodule in endometrial carcinoma: Detection with FDG PET-CT. Clin Nucl Med (In Press)
  • Singla S, Gupta S, Reddy RM, Durgapal P, Bal CS.68Ga-DOTA-NOC PET and Peptide Receptor Radionuclide Therapy in Management of Bilateral Ovarian Metastases from Gastrointestinal Carcinoid.Jpn J Clin Oncol. 2012 Oct 28. [Epub ahead of print]

    • Overview

  • Dr. G Rama Mohan Reddy is a distinguished nuclear medicine specialist in Yelahanka. He is currently practising as a Lead consultant - Nuclear Medicine at Manipal Hospitals, Yelahanka, bringing over 15 years of focused experience in PET-CT imaging, advanced molecular diagnostics, and therapeutic nuclear medicine. With an academic foundation as an MBBS graduate of Kurnool Medical College and an MD in Nuclear Medicine from the All India Institute of Medical Sciences (AIIMS), New Delhi, he has developed deep expertise in advanced nuclear imaging and radionuclide-based therapies. His structured MD training, followed by senior residency, laid the foundation for high-volume exposure to comprehensive nuclear medicine services, including diagnostic imaging, hybrid imaging technologies, and radionuclide therapy.

  • Dr. Reddy has extensive expertise in PET-CT imaging, having interpreted and supervised more than 50,000 18F-FDG PET-CT scans across oncology, cardiac, and neurological indications. His experience includes 68Ga DOTANOC imaging for neuroendocrine tumours (over 5000 cases), 68Ga PSMA imaging for prostate cancer, 18F-DOPA studies in brain tumours and movement disorders, 18F-NaF bone imaging, and 13N-ammonia myocardial perfusion imaging. This depth of hybrid imaging experience places him among the best nuclear medicine specialists in Yelahanka for oncological and molecular imaging services.

  • Beyond PET-CT, his general nuclear medicine work spans genitourinary scans, hepatobiliary imaging, endocrine evaluations, CNS imaging, skeletal studies, lymphoscintigraphy, RBC labelling, gastrointestinal applications, and lung perfusion studies. In nuclear cardiology, he has performed myocardial perfusion imaging using Tc-99m and Thallium tracers, viability assessments using FDG combinations, and radionuclide ventriculography.

  • Therapeutic nuclear medicine forms a significant component of his practice. He has extensive experience in radioiodine therapy for thyroid cancer and hyperthyroidism, with involvement in high patient volumes in dedicated thyroid clinics. His work also includes diagnosis and treatment of neuroendocrine tumours using 68Ga DOTANOC imaging and 177Lutetium therapy; prostate cancer management with 68Ga PSMA imaging and 177Lutetium therapy; 131I MIBG therapy for neuroblastoma and pheochromocytoma; 188Rhenium radiosynovectomy for chronic arthritic conditions; and bone pain palliation using 153Samarium and 89Strontium.

  • Dr. Reddy has several years of experience working with GE and Siemens nuclear imaging systems and is a qualified Radiological Safety Officer. His academic profile includes 13 indexed international publications, 10 international abstracts, and a book chapter contribution in nuclear medicine imaging. His research work spans oncologic PET-CT applications, hybrid SPECT-CT evaluation, thyroid disease management, and molecular imaging advancements.

  • At Manipal Hospital, Yelahanka, Dr. Reddy delivers comprehensive nuclear medicine services integrating advanced imaging, molecular diagnostics, and radionuclide therapy within a multidisciplinary oncology framework. His experience across high-volume PET-CT reporting, therapeutic isotope applications, and academic contributions positions him among the best nuclear medicine specialists in Yelahanka for advanced PET-CT and targeted radionuclide care.

    • Field of Expertise

  • PET-CT Imaging (FDG, PSMA, DOTANOC, DOPA, NaF)
  • Thyroid Cancer & Hyperthyroidism Management (131I Therapy)
  • Theranostics (177Lu Therapy for NET & Prostate Cancer)
  • Nuclear Cardiology & Myocardial Perfusion Imaging
  • Radiosynovectomy for Chronic Arthritis
  • Bone Pain Palliation Using 153Samarium & 89Strontium

    • Languages Spoken

  • English
  • Kannada
  • Telugu
  • Hindi

FAQ's

Patients visit Dr. G. Rama Mohan Reddy, a leading Lead consultant - Nuclear Medicine at Manipal Hospitals Yelahanka - Bengaluru, for expert care and advanced treatments. Known for accurate diagnoses and patient centric care, Dr. G. Rama Mohan Reddy is a trusted choice for exceptional medical support.

Home Yelahanka Doctors Dr-g-rama-mohan-reddy-nuclear-medicine-specialist

You’re on Our Indian Website

Visit the Global site for International patient services

Appointment
Health Check
Home Care
Contact Us
review icon
Review Us
Call Us